Qiagen Stock Price, News & Analysis (NASDAQ:QGEN)

$33.97 +0.41 (+1.22 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$33.97
Today's Range$33.38 - $34.01
52-Week Range$27.74 - $36.34
Volume688,207 shs
Average Volume1.24 million shs
Market Capitalization$7.84 billion
P/E Ratio199.82
Dividend YieldN/A
Beta1.03

About Qiagen (NASDAQ:QGEN)

Qiagen logoQIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNASDAQ:QGEN
CUSIPN7248210
Phone+31-77-3556600

Debt

Debt-to-Equity Ratio0.69%
Current Ratio5.07%
Quick Ratio4.59%

Price-To-Earnings

Trailing P/E Ratio199.823529411765
Forward P/E Ratio25.35
P/E Growth1.93

Sales & Book Value

Annual Sales$1.42 billion
Price / Sales5.47
Cash Flow$2.51 per share
Price / Cash13.53
Book Value$11.13 per share
Price / Book3.05

Profitability

Trailing EPS$0.17
Net Income$40.39 million
Net Margins2.85%
Return on Equity11.74%
Return on Assets6.28%

Miscellaneous

Employees4,684
Outstanding Shares228,230,000

Qiagen (NASDAQ:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the NASDAQ under the ticker symbol "QGEN."

How will Qiagen's stock buyback program work?

Qiagen announced that its Board of Directors has authorized a stock repurchase program on Thursday, February 1st 2018, which allows the company to buyback $200,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

How were Qiagen's earnings last quarter?

Qiagen NV (NASDAQ:QGEN) issued its quarterly earnings results on Monday, November, 6th. The company reported $0.32 earnings per share for the quarter, hitting analysts' consensus estimates of $0.32. The business earned $364 million during the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The business's revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 EPS. View Qiagen's Earnings History.

When will Qiagen make its next earnings announcement?

Qiagen is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Qiagen.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY18 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of $1.31-1.33 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.37. The company issued revenue guidance of approx $1.50-1.52 billion, compared to the consensus revenue estimate of $1.52 billion.Qiagen also updated its Q1 guidance to $0.23-0.24 EPS.

Where is Qiagen's stock going? Where will Qiagen's stock price be in 2018?

13 brokers have issued 1 year price objectives for Qiagen's stock. Their predictions range from $28.00 to $39.00. On average, they anticipate Qiagen's stock price to reach $34.88 in the next year. View Analyst Ratings for Qiagen.

Who are some of Qiagen's key competitors?

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:

  • Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)
  • Peer M. Schatz, Chief Executive Officer, Managing Director
  • Roland Sackers, Chief Financial Officer
  • Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
  • Thierry Bernard, Senior Vice President - Molecular Diagnostics Business Area
  • Laura Furmanski, Senior Vice President - Bioinformatics Business Area
  • Douglas Liu, Senior Vice President - Global Operations
  • Manuel O. Mendez, Senior Vice President - Global Commercial Operations
  • Stephane Bancel, Independent Supervisory Director (Age 44)
  • Hakan Bjorklund, Supervisory Board Director (Age 61)

Who owns Qiagen stock?

Qiagen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.22%), Deutsche Bank AG (5.00%), BlackRock Inc. (3.55%), Hardman Johnston Global Advisors LLC (1.57%), Frontier Capital Management Co. LLC (1.07%) and Atlanta Capital Management Co. L L C (0.55%). View Institutional Ownership Trends for Qiagen.

Who sold Qiagen stock? Who is selling Qiagen stock?

Qiagen's stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Franklin Resources Inc., Millennium Management LLC, WINTON GROUP Ltd and Bank of New York Mellon Corp. View Insider Buying and Selling for Qiagen.

Who bought Qiagen stock? Who is buying Qiagen stock?

Qiagen's stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Assenagon Asset Management S.A., Systematic Financial Management LP, FNY Partners Fund LP, Vident Investment Advisory LLC, Two Sigma Advisers LP, Cambiar Investors LLC and Bank of Montreal Can. View Insider Buying and Selling for Qiagen.

How do I buy Qiagen stock?

Shares of Qiagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of Qiagen stock can currently be purchased for approximately $33.97.

How big of a company is Qiagen?

Qiagen has a market capitalization of $7.84 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $0.17 on an earnings per share basis. Qiagen employs 4,684 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (QGEN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  644
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Qiagen (NASDAQ:QGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.462.422.422.42
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.88$34.00$33.36$32.56
Price Target Upside: 3.86% upside3.44% upside6.85% upside3.24% upside

Qiagen (NASDAQ:QGEN) Consensus Price Target History

Price Target History for Qiagen (NASDAQ:QGEN)

Qiagen (NASDAQ:QGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$38.00 -> $39.00LowView Rating Details
2/1/2018CommerzbankReiterated RatingBuyHighView Rating Details
1/29/2018Goldman Sachs GroupInitiated CoverageBuy -> Buy$39.00LowView Rating Details
1/22/2018Deutsche BankReiterated RatingBuyLowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform$35.00MediumView Rating Details
12/21/2017CowenReiterated RatingHold$34.00LowView Rating Details
12/19/2017DZ BankReiterated RatingNeutralLowView Rating Details
11/7/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/AView Rating Details
8/1/2017Independent ResearchUpgradeSell -> HoldLowView Rating Details
7/31/2017Jefferies GroupReiterated RatingHold$25.00 -> $28.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingNeutral$33.00 -> $36.00LowView Rating Details
7/17/2017BarclaysReiterated RatingOverweight$33.00 -> $37.00LowView Rating Details
7/13/2017Wells Fargo & CoReiterated RatingMarket Perform$28.00 -> $31.00LowView Rating Details
8/1/2016MizuhoBoost Price TargetNeutral$22.00 -> $25.00N/AView Rating Details
7/25/2016Piper Jaffray CompaniesReiterated RatingNeutral$23.00N/AView Rating Details
3/15/2016CitigroupLower Price TargetNeutral$28.00 -> $25.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Qiagen (NASDAQ:QGEN) Earnings History and Estimates Chart

Earnings by Quarter for Qiagen (NASDAQ:QGEN)

Qiagen (NASDAQ QGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018N/AView Earnings Details
11/6/2017Q3$0.32$0.32$363.42 million$364.00 millionViewN/AView Earnings Details
7/27/20176/30/2017$0.28$0.30$353.09 million$349.00 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.21$0.22$307.14 million$307.71 millionViewN/AView Earnings Details
2/1/2017Q416$0.34$0.39$372.70 million$366.50 millionViewListenView Earnings Details
11/2/2016Q316$0.28$0.29$335.46 million$338.70 millionViewN/AView Earnings Details
7/28/2016Q216$0.23$0.24$326.73 million$334.40 millionViewN/AView Earnings Details
4/27/2016Q116$0.19$0.19$295.76 million$298.40 millionViewN/AView Earnings Details
2/2/2016Q415$0.32$0.33$354.47 million$349.00 millionViewN/AView Earnings Details
1/2/2016Q4 2015$0.32$0.32$350.40 million$348.54 millionViewN/AView Earnings Details
10/28/2015Q315$0.28$0.27$323.50 million$314.60 millionViewListenView Earnings Details
7/29/2015Q215$0.25$0.26$319.43 million$319.50 millionViewListenView Earnings Details
5/7/2015Q115$0.22$0.22$304.60 million$298.70 millionViewN/AView Earnings Details
1/28/2015Q414$0.30$0.25$367.82 million$360.80 millionViewN/AView Earnings Details
10/29/2014Q3$0.27$0.27$337.00 million$336.80 millionViewN/AView Earnings Details
7/29/2014Q214$0.25$0.26$330.76 million$331.20 millionViewN/AView Earnings Details
5/7/2014Q114$0.22$0.22$317.09 million$317.40 millionViewN/AView Earnings Details
1/29/2014Q413$0.34$0.36$365.52 million$362.60 millionViewN/AView Earnings Details
10/29/2013Q313$0.25$0.28$320.37 million$323.80 millionViewN/AView Earnings Details
7/30/2013Q213$0.24$0.27$311.75 million$316.40 millionViewN/AView Earnings Details
4/29/2013Q113$0.23$0.23$305.50 million$303.60 millionViewN/AView Earnings Details
1/29/2013Q412$0.31$0.34$327.80 million$346.50 millionViewN/AView Earnings Details
11/5/2012Q312$0.24$0.26$303.79 million$304.30 millionViewN/AView Earnings Details
7/24/2012$0.25$0.25ViewN/AView Earnings Details
4/25/2012$0.21$0.23ViewN/AView Earnings Details
1/31/2012$0.28$0.31ViewN/AView Earnings Details
11/2/2011$0.22$0.24ViewN/AView Earnings Details
7/25/2011$0.23$0.23ViewN/AView Earnings Details
4/27/2011$0.21$0.21ViewN/AView Earnings Details
1/31/2011$0.25$0.26ViewN/AView Earnings Details
11/8/2010Q3 2010$0.24$0.25ViewN/AView Earnings Details
8/9/2010Q2 2010$0.22$0.21ViewN/AView Earnings Details
5/3/2010Q1 2010$0.20$0.21ViewN/AView Earnings Details
2/8/2010Q4 2009$0.23$0.25ViewN/AView Earnings Details
11/9/2009Q3 2009$0.24$0.26ViewN/AView Earnings Details
8/10/2009Q2 2009$0.22$0.24ViewN/AView Earnings Details
5/4/2009Q1 2009$0.20$0.20ViewN/AView Earnings Details
2/9/2009Q4 2008$0.22$0.21ViewN/AView Earnings Details
11/11/2008Q3 2008$0.20$0.22ViewN/AView Earnings Details
8/4/2008Q2 2008$0.20$0.21ViewN/AView Earnings Details
5/5/2008Q1 2008$0.16$0.19ViewN/AView Earnings Details
2/11/2008Q4 2007$0.15$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Qiagen (NASDAQ:QGEN) Earnings Estimates

2018 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.25$0.25$0.25
Q2 20181$0.32$0.32$0.32
Q3 20181$0.35$0.35$0.35
Q4 20181$0.44$0.44$0.44
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Qiagen (NASDAQ:QGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Qiagen (NASDAQ QGEN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Qiagen (NASDAQ QGEN) News Headlines

Source:
DateHeadline
QIAGEN Welcomes WHO’s New Global Guidelines on Latent TB ScreeningQIAGEN Welcomes WHO’s New Global Guidelines on Latent TB Screening
finance.yahoo.com - February 22 at 5:43 PM
BidaskClub Upgrades Qiagen (QGEN) to "Buy"BidaskClub Upgrades Qiagen (QGEN) to "Buy"
www.americanbankingnews.com - February 21 at 8:52 PM
QIAGEN Welcomes New Decision by U.S. Centers for Disease ... - Business Wire (press release)QIAGEN Welcomes New Decision by U.S. Centers for Disease ... - Business Wire (press release)
www.businesswire.com - February 21 at 8:11 AM
QIAGEN Welcomes New Decision by U.S. Centers for Disease Control to Use Modern Blood-Based TB Tests for Immigration ScreeningQIAGEN Welcomes New Decision by U.S. Centers for Disease Control to Use Modern Blood-Based TB Tests for Immigration Screening
finance.yahoo.com - February 20 at 5:54 PM
QIAGEN's QFT-Plus Approval in Japan to Expand Customer BaseQIAGEN's QFT-Plus Approval in Japan to Expand Customer Base
finance.yahoo.com - February 12 at 3:38 PM
Zacks: Analysts Anticipate Qiagen NV (QGEN) to Announce $0.24 EPSZacks: Analysts Anticipate Qiagen NV (QGEN) to Announce $0.24 EPS
www.americanbankingnews.com - February 11 at 11:20 PM
Qiagen (QGEN) Downgraded to C+ at TheStreetQiagen (QGEN) Downgraded to C+ at TheStreet
www.americanbankingnews.com - February 10 at 7:56 AM
QIAGEN’s QuantiFERON-TB Gold Plus gains approval in JapanQIAGEN’s QuantiFERON-TB Gold Plus gains approval in Japan
finance.yahoo.com - February 9 at 8:46 AM
Qiagen NV (QGEN) Receives Average Recommendation of "Hold" from AnalystsQiagen NV (QGEN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 9 at 8:30 AM
QIAGEN Launches Predictive Therascreen Pitx2 Test in Europe to Guide Treatment in High-Risk Breast CancerQIAGEN Launches Predictive Therascreen Pitx2 Test in Europe to Guide Treatment in High-Risk Breast Cancer
finance.yahoo.com - February 7 at 8:31 AM
Qiagen (QGEN) Raised to Hold at Zacks Investment ResearchQiagen (QGEN) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 6 at 2:08 PM
William Blair Research Analysts Decrease Earnings Estimates for Qiagen NV (QGEN)William Blair Research Analysts Decrease Earnings Estimates for Qiagen NV (QGEN)
www.americanbankingnews.com - February 5 at 5:28 AM
Jefferies Group Weighs in on Qiagen NVs Q1 2018 Earnings (QGEN)Jefferies Group Weighs in on Qiagen NV's Q1 2018 Earnings (QGEN)
www.americanbankingnews.com - February 5 at 1:52 AM
Qiagen NV (QGEN) PT Raised to $37.50 at Evercore ISI - StreetInsider.comQiagen NV (QGEN) PT Raised to $37.50 at Evercore ISI - StreetInsider.com
www.streetinsider.com - February 3 at 3:40 PM
Morgan Stanley Boosts Qiagen (QGEN) Price Target to $39.00Morgan Stanley Boosts Qiagen (QGEN) Price Target to $39.00
www.americanbankingnews.com - February 2 at 8:56 PM
Qiagen Tops Off 2017 With Solid Earnings and an AcquisitionQiagen Tops Off 2017 With Solid Earnings and an Acquisition
finance.yahoo.com - February 2 at 3:41 PM
QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues ViewQIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View
finance.yahoo.com - February 1 at 3:36 PM
Stock Repurchase Program Declared by Qiagen (QGEN) Board of Directors Stock Repurchase Program Declared by Qiagen (QGEN) Board of Directors
www.americanbankingnews.com - February 1 at 11:12 AM
QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share RepurchaseQIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase
finance.yahoo.com - February 1 at 8:52 AM
QIAGEN Enters into Agreement to Acquire STAT-Dx, Plans to Launch a Next-Generation, Fully Integrated Multiplex Platform for Syndromic Disease TestingQIAGEN Enters into Agreement to Acquire STAT-Dx, Plans to Launch a Next-Generation, Fully Integrated Multiplex Platform for Syndromic Disease Testing
finance.yahoo.com - February 1 at 8:52 AM
Qiagen reports 4Q lossQiagen reports 4Q loss
finance.yahoo.com - February 1 at 8:52 AM
Qiagen (QGEN) Releases FY18 Earnings GuidanceQiagen (QGEN) Releases FY18 Earnings Guidance
www.americanbankingnews.com - January 31 at 5:10 PM
Qiagen (QGEN) Releases Q1 Earnings GuidanceQiagen (QGEN) Releases Q1 Earnings Guidance
www.americanbankingnews.com - January 31 at 5:10 PM
Should You Buy QIAGEN NV (NYSE:QGEN) Now?Should You Buy QIAGEN NV (NYSE:QGEN) Now?
finance.yahoo.com - January 31 at 8:36 AM
Goldman Sachs: Qiagen Has Strategic Appeal, M&A PotentialGoldman Sachs: Qiagen Has 'Strategic Appeal,' M&A Potential
finance.yahoo.com - January 30 at 8:28 AM
Goldman Sachs Group Begins Coverage on Qiagen (QGEN)Goldman Sachs Group Begins Coverage on Qiagen (QGEN)
www.americanbankingnews.com - January 29 at 6:02 PM
$394.48 Million in Sales Expected for Qiagen NV (QGEN) This Quarter$394.48 Million in Sales Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - January 27 at 1:00 AM
Qiagen Reaches Analyst Target PriceQiagen Reaches Analyst Target Price
www.nasdaq.com - January 26 at 3:37 PM
FDA Nod for QIAGEN's JAK2 Test Boosts Molecular DiagnosticFDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic
finance.yahoo.com - January 26 at 3:37 PM
 Brokerages Anticipate Qiagen NV (QGEN) Will Announce Earnings of $0.42 Per Share Brokerages Anticipate Qiagen NV (QGEN) Will Announce Earnings of $0.42 Per Share
www.americanbankingnews.com - January 25 at 11:07 PM
Qiagen (QGEN) Scheduled to Post Earnings on WednesdayQiagen (QGEN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 24 at 3:56 AM
QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative NeoplasmsQIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms
finance.yahoo.com - January 23 at 4:43 PM
Qiagen (QGEN) Given Buy Rating at Deutsche BankQiagen (QGEN) Given Buy Rating at Deutsche Bank
www.americanbankingnews.com - January 22 at 9:20 AM
Qiagen (QGEN) Given "Buy" Rating at CommerzbankQiagen (QGEN) Given "Buy" Rating at Commerzbank
www.americanbankingnews.com - January 20 at 11:08 PM
Qiagen (QGEN) Announces FDA Approval to Expand Use of EGFR ... - StreetInsider.comQiagen (QGEN) Announces FDA Approval to Expand Use of EGFR ... - StreetInsider.com
www.streetinsider.com - January 19 at 3:28 PM
QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung CancerQIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer
finance.yahoo.com - January 19 at 9:14 AM
Analyzing Qiagen (QGEN) & Cellular Dynamics International (ICEL)Analyzing Qiagen (QGEN) & Cellular Dynamics International (ICEL)
www.americanbankingnews.com - January 18 at 1:32 PM
QIAGEN N.V. to Report Fourth Quarter and Full Year of 2017 ResultsQIAGEN N.V. to Report Fourth Quarter and Full Year of 2017 Results
finance.yahoo.com - January 18 at 8:07 AM
Qiagen (QGEN) & WuXi PharmaTech (Cayman) (WX) Head to Head AnalysisQiagen (QGEN) & WuXi PharmaTech (Cayman) (WX) Head to Head Analysis
www.americanbankingnews.com - January 17 at 1:50 PM
Head-To-Head Survey: Qiagen (QGEN) vs. Covance (CVD)Head-To-Head Survey: Qiagen (QGEN) vs. Covance (CVD)
www.americanbankingnews.com - January 16 at 9:32 AM
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm - NasdaqQIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm - Nasdaq
www.nasdaq.com - January 16 at 8:05 AM
HTG Molecular Announces Third Statement of Work for New Clinical Assay Development ProgramHTG Molecular Announces Third Statement of Work for New Clinical Assay Development Program
finance.yahoo.com - January 16 at 8:05 AM
Qiagen NV (QGEN) Given Consensus Rating of "Hold" by AnalystsQiagen NV (QGEN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 15 at 7:42 AM
Financial Review: WuXi PharmaTech (Cayman) (WX) and Qiagen (QGEN)Financial Review: WuXi PharmaTech (Cayman) (WX) and Qiagen (QGEN)
www.americanbankingnews.com - January 12 at 11:30 AM
Qiagens (QGEN) "Buy" Rating Reiterated at CommerzbankQiagen's (QGEN) "Buy" Rating Reiterated at Commerzbank
www.americanbankingnews.com - January 10 at 8:36 AM
 Brokerages Anticipate Qiagen NV (QGEN) Will Post Quarterly Sales of $392.98 Million Brokerages Anticipate Qiagen NV (QGEN) Will Post Quarterly Sales of $392.98 Million
www.americanbankingnews.com - January 10 at 6:04 AM
QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis ... - PR Newswire (press release)QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis ... - PR Newswire (press release)
www.prnewswire.com - January 9 at 8:21 AM
QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio EnhancementsQIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements
finance.yahoo.com - January 8 at 11:10 AM
QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer SystemsQIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems
finance.yahoo.com - January 8 at 11:10 AM
With A Recent ROE Of 3.39%, Can QIAGEN NV (NASDAQ:QGEN) Catch Up To Its Industry?With A Recent ROE Of 3.39%, Can QIAGEN NV (NASDAQ:QGEN) Catch Up To Its Industry?
finance.yahoo.com - January 8 at 11:10 AM

SEC Filings

Qiagen (NASDAQ:QGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Qiagen (NASDAQ:QGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Qiagen (NASDAQ QGEN) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.